MNTA Momenta Pharmaceuticals Inc.

15.1
+1.19  (+9%)
Previous Close 13.91
Open 14.47
Price To Book 5.97
Market Cap 1486901470
Shares 98,470,296
Volume 1,050,253
Short Ratio
Av. Daily Volume 878,076

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial met primary endpoint - November 29, 2016.
M923
Moderate-to-severe chronic plaque psoriasis
Filed 2007. Approved April 16 2015.
Generic Copaxone
Multiple sclerosis
Phase 2 development discontinued due to poor efficacy shown
Necuparanib (MOM-M402-103)
Advanced metastatic pancreatic cancer
Phase 1 trial to be completed 2019.
M230 (CSL730)
Healthy volunteers
Phase 2 data due 2020.
M281
generalized myasthenia gravis (gMG)
Phase 2 data due 2021.
M281
hemolytic disease of the fetus and newborn (HDFN)
Phase 1/2 dosing has commenced - noted January 29, 2019. Initial data due 1H 2020.
M254
Immune Thrombocytopenic Purpura (ITP)

Latest News

  1. Edited Transcript of MNTA earnings conference call or presentation 22-Feb-19 1:30pm GMT
  2. Momenta Pharmaceuticals (MNTA) Reports Q4 Loss, Tops Revenue Estimates
  3. Momenta: 4Q Earnings Snapshot
  4. Momenta Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
  5. Analysts Estimate Momenta Pharmaceuticals (MNTA) to Report a Decline in Earnings: What to Look Out for
  6. See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc.
  7. Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2018 Financial Results Conference Call and Webcast
  8. Momenta Pharmaceuticals Announces Oral Presentation of New Data for M281 at the Society for Maternal-Fetal Medicine 2019 Annual Meeting
  9. Momenta Pharmaceuticals Announces First Subject Dosed in Phase 1/2 Clinical Trial of M254, Hypersialylated Immunoglobulin G
  10. New Research Coverage Highlights Lennox International, Momenta Pharmaceuticals, Westlake Chemical Partners LP, Symantec, American Eagle Outfitters, and FTD Companies — Consolidated Revenues, Company Growth, and Expectations for 2019
  11. What Investors Should Know About Momenta Pharmaceuticals, Inc.’s (NASDAQ:MNTA) Financial Strength
  12. Momenta Pharmaceuticals to Webcast Presentation at the 37th Annual J.P. Morgan Healthcare Conference
  13. Here is What Hedge Funds Think About Momenta Pharmaceuticals, Inc. (MNTA)
  14. Edited Transcript of MNTA earnings conference call or presentation 7-Nov-18 1:00pm GMT
  15. Here's Why Momenta Pharmaceuticals Fell for a Second Straight Day
  16. Momenta Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares
  17. Teva (TEVA) Stock Poised to Record Big Gains in 2019?
  18. Here's Why Momenta Pharmaceuticals Jumped 18% on Friday